Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 83.57 percent increase over losses of $(2.07) per
Tempest Therapeutics lost more money per share than experts predicted, though it's losing way less than it did a year ago. When a company misses what people expected, it's worth noticing—but also check if they're improving over time, like Tempest is.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.